Latest Industry News & Trends

Market Scope provides comprehensive coverage of the ophthalmic market. Our news stories are a combination of public and proprietary content ranging from coverage of international meetings, surgeon survey results and trends, analysis of company financial reports and public medical registries, press releases, and interviews with companies executive. Register today to receive free weekly email updates, our top data chart, surgeon poll results, and much more. Locked content can be accessed through a subscription to our ophthalmic industry newsletters.

Recently Added News

4/14/2021
Press Release
US Cataract Pharmaceuticals Evolve in Drug Delivery
US Cataract Pharmaceuticals Evolve in Drug Delivery

US cataract surgeons showed a preference for incremental improvement in drug delivery over revolutionary change in the first full year for three new corticosteroid products to manage inflammation a...

4/16/2021
BreakingDealsInstrumentsSurgical
Katena Buys ASICO, Building on Roster of Recent Acquisitions
Katena Buys ASICO, Building on Roster of Recent Acquisitions

Katena Products announced April 14 that it had purchased fellow ophthalmic surgical instrument maker ASICO, of Westmont, Illinois. The companies said ASICO’s product portfolio comprises more than 1...

4/16/2021
BreakingDealsPharmaRetina
Alimera Licenses its Steroid Implant to Ocumension for Asian Markets, Receives $20 Million
Alimera Licenses its Steroid Implant to Ocumension for Asian Markets, Receives $20 Million

Alimera Sciences announced April 14 that China’s Ocumension Therapeutics had paid $10 million up front to license Alimera’s 0.19 mg fluocinolone acetonide intravitreal implant, which Alimera market...

4/16/2021
BreakingClinical TrialDry EyePharma
Bausch + Lomb Dry Eye Candidate Licensed from Novaliq Meets All Endpoints in Phase III Trial
Bausch + Lomb Dry Eye Candidate Licensed from Novaliq Meets All Endpoints in Phase III Trial

Bausch + Lomb, a division of Canada’s Bausch Health, and Germany’s Novaliq announced April 13 statistically significant topline data from the first Phase III trial of NOV03 (perfluorohexyloctane) f...

4/16/2021
BreakingDiagnostic
AAO, NEI, Others Urge Ophthalmic Equipment Manufacturers to Standardize Digital Imaging
AAO, NEI, Others Urge Ophthalmic Equipment Manufacturers to Standardize Digital Imaging

The American Academy of Ophthalmology published a report April 5 urging ophthalmic imaging device manufacturers to standardize image formats to comply with the Digital Imaging and Communications in...

4/16/2021
BreakingCataractRegulationSurgical
J&J Vision Surgical Gains US Clearance for Veritas Next-Generation Phaco System
J&J Vision Surgical Gains US Clearance for Veritas Next-Generation Phaco System

Johnson & Johnson Vision Surgical gained US FDA 510(k) clearance on March 12 for its Veritas Vision System. The phacoemulsification system is an updated version of the company’s WhiteStar Signature...

4/16/2021
BreakingCataractIOLSurgical
Alcon Introduces UV-Filtering Versions of PanOptix, Vivity IOLs in Canada
Alcon Introduces UV-Filtering Versions of PanOptix, Vivity IOLs in Canada

Alcon announced on April 12 that it had launched in Canada four next-generation IOLs to provide ultraviolet (UV)-filtering hydrophobic protection. The models are the AcrySof IQ PanOptix UV intraocu...

4/16/2021
BreakingDealsGene TherapyRetina
AGTC Licenses X-Linked Retinoschisis Gene Therapy Program to TeamedOn
AGTC Licenses X-Linked Retinoschisis Gene Therapy Program to TeamedOn

Applied Genetic Technologies Corporation (AGTC) announced April 13 that it had reached a licensing deal with TeamedOn International to advance a gene therapy candidate to treat X-linked retinoschis...

4/16/2021
BreakingClinical TrialPharmaRetina
Apellis Sees Positive Results with Pegcetacoplan at 24 Months in GA
Apellis Sees Positive Results with Pegcetacoplan at 24 Months in GA

Apellis Pharmaceuticals on April 13 reported 24-month data from its Phase Ib study of pegcetacoplan. The targeted C3 therapy is under investigation as a treatment for bilateral advanced geographic ...

4/16/2021
BreakingClinical TrialGlaucomaPharma
Qlaris Bio Enrolls First Patient in Phase I/II Studies of Glaucoma Candidate
Qlaris Bio Enrolls First Patient in Phase I/II Studies of Glaucoma Candidate

Qlaris Bio announced April 15 that it had enrolled the first patient in the Phase I/II clinical program for QLS-101, an investigational therapy designed to lower intraocular pressure (IOP) by reduc...

4/16/2021
BreakingFundingPharmaSurgical
Harrow Health Announces Public Offering of $50 Million in Senior Notes
Harrow Health Announces Public Offering of $50 Million in Senior Notes

Harrow Health announced April 15 that it has commenced an underwritten registered public offering of $50 million in senior notes due 2026. The company, based in Nashville, Tennessee, said it expect...

4/9/2021
BreakingClinical TrialGene TherapyRetina
Bionic Sight Reports Light Sensitivity in RP Patients Treated with Gene Therapy Candidate
Bionic Sight Reports Light Sensitivity in RP Patients Treated with Gene Therapy Candidate

Bionic Sight, of New York, reported March 30 that the first four patients treated with its gene therapy candidate for retinitis pigmentosa were able to detect light and motion, and two could detect...

Past News Stories

4/9/2021
BreakingCataractSingle-UseSurgical
US FDA Approves Bausch + Lomb’s ClearVisc Dispersive OVD
US FDA Approves Bausch + Lomb’s ClearVisc Dispersive OVD

Bausch + Lomb announced April 7 that the US FDA had approved its ClearVisc dispersive ophthalmic viscosurgical device (OVD) for use in ophthalmic surgery. OVDs aid in cataract extraction and intrao...

4/9/2021
BreakingGene TherapyRegulationRetina
Chinese Regulators Approve IND for Neurophth’s LHON Gene Therapy Candidate
Chinese Regulators Approve IND for Neurophth’s LHON Gene Therapy Candidate

Neurophth Biotechnology announced April 1 that the China National Medical Products Administration had approved the company’s investigational new drug (IND) application for its gene therapy candidat...

4/9/2021
BreakingFundingPharmaRetina
Oxurion Secures Capital Commitment of up to $35.8 Million from Negma Group
Oxurion Secures Capital Commitment of up to $35.8 Million from Negma Group

Belgium’s Oxurion announced April 6 that it had agreed to a capital commitment of up to €30 million (US $35.8 million) from Negma Group. Negma Group is a growth-focused debt and equity firm based i...

4/9/2021
BreakingFundingGene TherapyRetina
ProQR Raises $103.5 Million After Full Exercise of Underwriters’ Option
ProQR Raises $103.5 Million After Full Exercise of Underwriters’ Option

Netherlands-based ProQR Therapeutics announced April 5 that it had closed an underwritten public offering of 13,846,154 ordinary shares at $6.50 per share. Underwriters fully exercised their option...

4/5/2021
BreakingDealsDeviceRetina
Pixium, Second Sight Merger Deal Falls Apart in Flap over Private Placement
Pixium, Second Sight Merger Deal Falls Apart in Flap over Private Placement

Pixium Vision announced April 3 that the merger deal between it and fellow retinal implant company Second Sight had been scrapped, following a controversial private placement closed by Second Sight...

4/2/2021
BreakingPharmaRegulation
Horizon Says it Will Resupply Market with Tepezza Beginning in April
Horizon Says it Will Resupply Market with Tepezza Beginning in April

Horizon Therapeutics announced March 30 that the US FDA had approved a prior approval supplement (PAS) giving Horizon authorization to manufacture more Tepezza, resulting in an increased number of ...

4/2/2021
BreakingDeviceSurgical
Zeiss’ $180 Million Innovation Center Opens Near San Francisco
Zeiss’ $180 Million Innovation Center Opens Near San Francisco

German company Zeiss announced March 31 that it had opened its Zeiss Innovation Center, a newly constructed facility built on 13.5 acres in Dublin, California, near San Francisco. The $180 million ...

4/2/2021
BreakingClinical TrialDry EyePharma
Hovione’s Minocycline for Inflamed MGD Shows Promise in Phase II Trial
Hovione’s Minocycline for Inflamed MGD Shows Promise in Phase II Trial

Hovione announced March 17 that it had completed a Phase II clinical trial of an ophthalmic formulation of minocycline in 270 patients with dry eye caused by meibomian gland dysfunction (MGD). The ...

4/2/2021
BreakingDealsDry Eye
Tarsus, LianBio Partner on Demodex Blepharitis, MGD Candidate in Greater China
Tarsus, LianBio Partner on Demodex Blepharitis, MGD Candidate in Greater China

Tarsus Pharmaceuticals, of Irvine, California, announced March 29 that it had formed a partnership with Chinese biotech company LianBio to develop and commercialize Tarsus’ TP-03 in the Greater Chi...

4/2/2021
BreakingDealsFundingIOLPharmaRetina
AffaMed Raises More than $170 Million in Series B, Makes Deal to Market SIFI IOLs in Greater China
AffaMed Raises More than $170 Million in Series B, Makes Deal to Market SIFI IOLs in Greater China

AffaMed Therapeutics announced March 30 that it had raised more than $170 million in a Series B financing. The oversubscribed round was led by Lake Bleu Capital, with participation by new investors...

4/2/2021
BreakingFundingGene TherapyRetina
ProQR Prices $90 Million Underwritten Public Offering
ProQR Prices $90 Million Underwritten Public Offering

Netherlands-based ProQR Therapeutics announced March 30 that it had priced an underwritten public offering of 13,846,154 ordinary shares at $6.50 per share. The company has also granted the underwr...

4/2/2021
BreakingFundingGene TherapyRetina
Gyroscope Therapeutics Raises $148 Million in Series C Financing
Gyroscope Therapeutics Raises $148 Million in Series C Financing

UK-based gene therapy company Gyroscope Therapeutics announced March 26 that it had raised $148 million in a Series C financing. The round was led by Forbion’s Growth Opportunities Fund and include...

Want to Read the Full Article?

Register A Corporate Account

A corporate account gives you access to licensed reports and subscriptions, the latest news, a personalized dashboard, and weekly emails with news and data.

Select one or more
Select one or more